HilleVax, Inc. announced the appointment of Ozzie Berger as Senior Vice President of Regulatory Affairs, the promotion of Anju Chatterji to Chief Technical Officer. As part of a planned transition in connection with Mr. Maltbie's promotion, David Socks will focus on business development activities as the company's Chief Business Officer. Mr. Berger brings to HilleVax nearly three decades of expertise in creating and implementing innovative regulatory strategies across all phases of product development and commercialization.

Prior to joining HilleVax, Mr. Berger was Vice President and Global Regulatory Head for GSK's Vaccine Therapeutic Group, where he led a team whose portfolio included over 40 vaccines worldwide. Mr. Berger was at GSK for over 21 years holding various leadership positions of increasing responsibility within the organization. Prior to GSK, Mr. Berger worked in the regulatory affairs group at Merck.Dr. Chatterji has more than 20 years of experience implementing CMC development and manufacturing strategies to drive successful global regulatory filings and approvals.

She served as Senior Vice President of Technical Operations for HilleVax since joining the company in January 2022. Prior to joining HilleVax, Dr. Chatterji served as SVP of Biologics Development and Manufacturing at Catalyst Biosciences. Prior to Catalyst Biosciences, Dr. Chatterji served as VP of Biologics Manufacturing at Exelixis.

Previously, Dr. Chatterji held various leadership positions at Grifols, Novartis Vaccines and Diagnostics, and at Bayer HealthCare.